Глава 14. Саркоидоз

Drent M., Cremers J.P., Jansen T.L., Baughman R.P. Practical eminence and experience-based recommendations for use of TNF-alpha inhibitors in sarcoidosis // Sarcoidosis Vasc. Diffuse Lung Dis. 2014. Vol. 31. N. 2. P. 91–107.

Dubaniewicz A. “Danger theory” as a common mechanism of sarcoidosis induction by infectious and non-infectious factors — a role of environmental factors and autoimmunity // Pol. Merkur. Lekarski. 2018. Vol. 44. N. 261. P. 97–100.

Dubrey S., Sharma R., Underwood R. et al. Sarcoidosis of the cardio-pulmonary systems // Clin. Med. (Lond.). 2016. Vol. 16. N. 1. P. 34–41. DOI: https://doi.org/10.7861/clinmedicine.16-1-34.

Duong H., Bonham C.A. Sarcoidosis-associated pulmonary hypertension: pathophysiology, diagnosis, and treatment // Clin. Pulm. Med. 2018. Vol. 25. N. 2. P. 52–60. DOI: https://doi.org/10.1097/CPM.0000000000000252.

El Sayed F., Torbey G., Youssef H., Chababi M. Childhood sarcoidosis: diagnostic issues // Dermatol. Online J. 2013. Vol. 19. N. 10. Article ID 20037.

Esteves T., Aparicio G., Garcia-Patos V. Is there any association between Sarcoidosis and infectious agents? A systematic review and meta-analysis // BMC Pulm. Med. 2016. Vol. 16. N. 1. P. 165. DOI: https://doi.org/10.1186/s12890-016-0332.

Fretzayas A., Moustaki M., Vougiouka O. The puzzling clinical spectrum and course of juvenile sarcoidosis // World J. Pediatr. 2011. Vol. 7. N. 2. P. 103–110.

Garcia Ródenas M.D.M., Gayá Garcia-Manso I., Garcia Sevila R. Sarcoidosis associated with Interferon beta treatment // Med. Clin. (Barc.). 2019. Vol. 153. N. 5. P. e21–e22. DOI: https://doi.org/10.1016/j.medcli.2018.11.021.

Gavrysyuk V., Merenkova E., Gumeniuk G. et al. Effectiveness and safety of methotrexate monotherapy in patients with pulmonary sarcoidosis // Georgian Med. News. 2018. Vol. 283. P. 34–38.

Ghrenassia E., Mekinian A., Chapelon-Albric C. et al. Digestive-tract sarcoidosis: French nationwide case-control study of 25 cases // Medicine (Baltimore). 2016. Vol. 95. N. 29. Article ID e4279.

Grunewald J. Genetics of sarcoidosis // Curr. Opin. Pulm. Med. 2008. Vol. 14. N. 5. P. 434–439.

Hamzeh N., Voelker A., Forssen A. et al. Efficacy of mycophenolate mofetil in sarcoidosis // Respir. Med. 2014. Vol. 108. P. 1663–1669.

Hetzel J., Maldonado F., Ravaglia C. et al. Transbronchial cryobiopsies for the diagnosis of diffuse parenchymal lung diseases: expert statement from the Cryobiopsy Working Group on Safety and Utility and a call for standardization of the procedure // Respiration. 2018. Vol. 95. N. 3. P. 188–200. DOI: https://doi.org/10.1159/000484055.

Hoffman A.L., Milman N., Byg K.E. Childhood sarcoidosis in Denmark 1979–1994: incidence, clinical features and laboratory results at presentation in 48 children // Acta Paediatr. 2004. Vol. 93. P. 30–36.

Hu Y., Yibrehu B., Zabini D., Kuebler W.M. Animal models of sarcoidosis // Cell Tissue Res. 2017. Vol. 367. N. 3. P. 651–661. DOI: https://doi.org/10.1007/s00441-016-2526-3.

Ibitoye R.T., Wilkins A., Scolding N.J. Neurosarcoidosis: a clinical approach to diagnosis and management // J. Neurol. 2017. Vol. 264. N. 5. P. 1023–1028. DOI: https://doi.org/10.1007/s00415-016-8336-4.

James D.G., Jones Williams W. (eds). Sarcoidosis and Other Granulomatous Disorders. Philadelphia: Saunders, 1985. P. 163–166.

James W.E., Baughman R. Treatment of sarcoidosis: grading the evidence // Expert Rev. Clin. Pharmacol. 2018. Vol. 11. N. 7. P. 677–687. DOI: https://doi.org/10.1080/17512433.2018.1486706.

Johannson K.A., Marcoux V.S., Ronksley P.E., Ryerson C.J. Diagnostic yield and complications of transbronchial lung cryobiopsy for interstitial lung disease. A systematic review and meta-analysis // Ann. Am. Thorac. Soc. 2016. Vol. 13. N. 10. P. 1828–1838.

Jouni H., Chareonthaitawee P. Unraveling inflammation and oxidative stress in cardiac sarcoidosis // Circ. Cardiovasc. Imaging. 2017. Vol. 10. N. 12. Article ID e007287. DOI: https://doi.org/10.1161/CIRCIMAGING.117.007287.

Judson M.A. The clinical features of sarcoidosis: a comprehensive review // Clin. Rev. Allergy Immunol. 2015. Vol. 49. N. 1. P. 63–78. DOI: https://doi.org/10.1007/s12016-014-8450-y.

Judson M.A., Baughman R.P., Costabel U. et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis // Eur. Respir. J. 2014. Vol. 44. P. 1296–1307.

Jung J.H., Kim J.H., Song G.G. Adalimumab-induced pulmonary sarcoidosis not progressing upon treatment with etanercept // Z. Rheumatol. 2017. Vol. 76. N. 4. P. 372–374. DOI: https://doi.org/10.1007/s00393-016-0262-4.

Katta R., Nelson B., Chen D., Roenigk H. Sarcoidosis of the scalp: a case series and review of the literature // J. Am. Acad. Dermatol. 2000. Vol. 42. P. 690–692.

Kiedrowicz M., Kacalak-Rzepka A., Bielecka-Grzela S., Maleszka R. Antimalarial drugs in contemporary dermatologic therapy // Ann. Acad. Med. Stetin. 2011. Vol. 57. N. 1. P. 38–44.

Kikuchi N., Nunoda S., Serizawa N. et al. Combination therapy with corticosteroid and mycophenolate mofetil in a case of refractory cardiac sarcoidosis // J. Cardiol. Cases. 2016. Vol. 13. N. 4. P. 125–128. DOI: https://doi.org/10.1016/j.jccase.2015.12.008.

Kim T.K., Kang S.H., Moon H.S. et al. Pulmonary sarcoidosis that developed during the treatment of a patient with Crohn disease by using infliximab // Ann. Coloproctol. 2017. Vol. 33. N. 2. P. 74–77. DOI: https://doi.org/10.3393/ac.2017.33.2.74.

Körber M., Kamp S., Kothe H. et al. Pentoxifylline inhibits secretion of O2- and TNF-alpha by alveolar macrophages in patients with sarcoidosis // Immun. Infekt. 1995. Vol. 23. N. 3. P. 107–110.

Landi C., Carleo A., Cillis G., Rottoli P. Sarcoidosis: proteomics and new perspectives for improving personalized medicine // Expert Rev. Proteomics. 2018. Vol. 15. N. 10. P. 829–835. DOI: https://doi.org/10.1080/14789450.2018.1528148.

Lentz R.J., Argento A.C., Colby T.V. et al. Transbronchial cryobiopsy for diffuse parenchymal lung disease: a state-of-the-art review of procedural techniques, current evidence, and future challenges // J. Thorac. Dis. 2017. Vol. 9. N. 7. P. 2186–2203. DOI: https://doi.org/10.21037/jtd.2017.06.96.

Lewis S.J., Ainslie G.M., Bateman E.D. Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosis // Sarcoidosis Vasc. Diffuse Lung Dis. 1999. Vol. 16. P. 87–92.

Löffler C., Bergner R. Sarcoidosis: renal manifestations // Z. Rheumatol. 2017. Vol. 76. N. 5. P. 398–407. DOI: https://doi.org/10.1007/s00393-017-0301-9.

Madan K., Dhungana A., Mohan A. et al. Conventional transbronchial needle aspiration versus endobronchial ultrasound-guided transbronchial needle aspiration, with or without rapid on-site evaluation, for the diagnosis of sarcoidosis: a randomized controlled trial // J. Bronchology Interv. Pulmonol. 2017. Vol. 24. N. 1. P. 48–58.

Madaule S., Lauque D., Sailler L. et al. Splenomegaly in sarcoidosis: clinical features and outcome. Analysis of 17 cases // Rev. Med. Interne. 2004. Vol. 25. N. 5. P. 348–356.

Majjad A., Bezza A., Biyi A. et al. Pulmonary sarcoidosis following etanercept treatment for ankylosing spondylitis: a case report and review of the literature // Case Rep. Rheumatol. 2018. Vol. 2018. Article ID 9867248. DOI: https://doi.org/10.1155/2018/9867248.

Marchetti M., Baker M.G., Noland M.M. Treatment of subcutaneous sarcoidosis with hydroxychloroquine: report of 2 cases // Dermatol. Online J. 2014. Vol. 20. N. 1. Article ID 21250.

Matsou A., Tsaousis K.T. Management of chronic ocular sarcoidosis: challenges and solutions // Clin. Ophthalmol. 2018. Vol. 12. P. 519–532. DOI: https://doi.org/10.2147/OPTH.S128949.

Morimoto T., Azuma A., Abe S. et al. Epidemiology of sarcoidosis in Japan // Eur. Respir. J. 2008. Vol. 31. N. 2. P. 372–379.

Niedoszytko P. Rehabilitation of patients with sarcoidosis // Pol. Merkur. Lekarski. 2018. Vol. 44. N. 261. P. 150–151.

Paramothayan N., Lasserson T., Jones P. Corticosteroids for pulmonary sarcoidosis // Cochrane Database Syst. Rev. 2005. Vol. 2. CD001114.

Parikh K.S., Dahhan T., Nicholl L. et al. Clinical features and outcomes of patients with sarcoidosis-associated pulmonary hypertension // Sci. Rep. 2019. Vol. 9. N. 1. P. 4061. DOI: https://doi.org/10.1038/s41598-019-40030-w.

Park M.K., Fontana Jr, Babaali H. et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis // Sarcoidosis Vasc. Diffuse Lung Dis. 2009. Vol. 26. N. 2. P. 121–131.

Patterson K.C., Chen E.S. The pathogenesis of pulmonary sarcoidosis and implications for treatment // Chest. 2018. Vol. 153. N. 6. P. 1432–1442. DOI: https://doi.org/10.1016/j.chest.2017.11.030.

Popova E.N., Bolevich S.B., Fomin V.V. et al. Pulmonary hypertension associated with sarcoidosis and experience of treatment with pentoxifylline (Vasonite) // Eur. Respir. J. 2006. Vol. 28. Suppl. 50. Ref. P2491.

Rabinowitz M.P., Murchison A.P. Orbital sarcoidosis treated with hydroxychloroquine // Orbit. 2011. Vol. 30. N. 1. P. 13–15. DOI: https://doi.org/10.3109/01676830.2010.524268.

Raj R., Nugent K. Leflunomide-induced interstitial lung disease (a systematic review) // Sarcoidosis Vasc. Diffuse Lung Dis. 2013. Vol. 30. N. 3. P. 167–176.

Refiskaya N.V., Stepanenko T.A., Jablonskiy P.K., Baranova O.P. The use of tumor necrosis factor alpha inhibitor pentoxifylline in the treatment of patients with I and II stages of pulmonary sarcoidosis // Eur. Respir. J. 2006. Vol. 28. Suppl. 50. Ref. E3134.

Rosenthal D.G., Anderson M.E., Petek B.J. et al. Invasive hemodynamics and rejection rates in patients with cardiac sarcoidosis after heart transplantation // Can. J. Cardiol. 2018. Vol. 34. N. 8. P. 978–982. DOI: https://doi.org/10.1016/j.cjca.2018.03.021.

Ruža I., Lucāne Z. Serum and urinary calcium level in Latvian patients with sarcoidosis // Reumatologia. 2018. Vol. 56. N. 6. P. 377–381. DOI: https://doi.org/10.5114/reum.2018.80715.

Sahoo D.H., Bandyopadhyay D., Xu M. et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis // Eur. Respir. J. 2011. Vol. 38. N. 5. P. 1145–1150. DOI: https://doi.org/10.1183/09031936.00195010.

Sahu P., Sharma S., Sharma N., Sharma S., Garg S. Unusual clinical presentations in early-onset childhood sarcoidosis: a correlation or coincidence? // J. Clin. Diagn. Res. 2017. Vol. 11. N. 8. P. WD01–WD03. DOI: https://doi.org/10.7860/JCDR/2017/27841.10389.

Salamo O., Roghaee S., Schweitzer M.D. et al. White donor, younger donor and double lung transplant are associated with better survival in sarcoidosis patients // Sci. Rep. 2018. Vol. 8. N. 1. P. 6968. DOI: https://doi.org/10.1038/s41598-018-25144-x.

Scherholz M.L., Schlesinger N., Androulakis I.P. Chronopharmacology of glucocorticoids // Adv. Drug Deliv. Rev. 2019. Vol. 151–152. P. 245–261. DOI: https://doi.org/10.1016/j.addr.2019.02.004. Epub 2019 Feb 21.